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Abstract
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The synthesis of both pro-inflammatory leukotrienes and anti-inflammatory lipoxins requires the
enzyme 5-lipoxygenase (5-LOX). 5-LOX activity is short-lived, apparently in part due to an
intrinsic instability of the enzyme. We identified a 5-LOX-specific destabilizing sequence that is
involved in orienting the carboxy-terminus which binds the catalytic iron. Herein we report the
crystal structure at 2.4 Å resolution of human 5-LOX stabilized by replacement of this sequence.
Leukotrienes (LT) and lipoxins are potent mediators of the inflammatory response derived
from arachidonic acid (AA). When leukocytes are activated, arachidonic acid is released
from the nuclear membrane by the action of cytosolic phospholipase A2 and binds fivelipoxygenase-activating protein (FLAP). The increased Ca2+ concentration of the activated
cells simultaneously promotes translocation of 5-LOX to the nuclear membrane where it
acquires its substrate from FLAP (1, 2). Arachidonic acid (AA) is converted to leukotriene
(LTA4) in a two-step reaction which produces the 5S-isomer of hydroperoxyeicosatetraenoic
acid (5S-HPETE) as an intermediate (3, 4).
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Auto-inactivation of 5-LOX activity has been described, and this loss of activity is perhaps
important in limiting the synthesis of its pro- and anti-inflammatory products (5). Previous
reports indicate that non-turnover based inactivation is a consequence of an O2 sensitivity
linked to the oxidation state of the catalytic iron (6). However, not all LOXs display this
hypersensitivity to O2. For example, 8R-LOX activity is stable despite a solvent exposed
iron coordination sphere equivalent to that in 5-LOX (7). In similar conditions 50% of 5LOX activity is lost in 10 hours (8). We reasoned that 5-LOX specific destabilizing features
may confer susceptibility to non-turnover based inactivation. Regulatory mechanisms that
facilitate transient activation include targeted degradation, phosphorylation, and allosteric
control of enzyme activities. Auto-inactivation as a consequence of intrinsic protein
instability may play a similar role. For example, the instability of the tumor suppressor
protein p53, relative to its orthologs such as p73, has been proposed to have a functional role
(9).
Based on the crystal structures of two AA-metabolizing lipoxygenases [an 8R-LOX from
Plexaura homomalla (7, 10) and a 15-LOX from rabbit reticulocyte (11, 12)], each with
~40% sequence identity to 5-LOX), we identified a 5-LOX specific lysine-rich region near
the C-terminus of the enzyme that might confer instability. In the 8R- and 15-LOX
structures, a turn centered on amino acid 655 (5-LOX numbering) leads from the C-terminal
helix to the carboxyl terminal segment, allowing the terminal carboxylate to penetrate the
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LOX body and bind the catalytic iron (Fig 1A, 1B). In most LOXs, amino acid 655 is a
highly conserved Leu, with its side chain pointing toward an invariant Arg (651). A striking
5-LOX specific feature is Lys in place of Leu at this position as part of a di- or tri- Lys
peptide (Fig S1). While numerous salt links anchor the C-terminal helix to the body of the
protein in the structures of the two homologues noted above, none of these salt links is
conserved in the 5-LOX sequence. As a consequence of the lysine-rich sequence and the
absence of helix-anchoring salt-links, the orientation of the terminal helix is less favorable
and the C-terminal ligand to the active site Fe is likely to be tenuously restrained.
Conservative mutations in the carboxy terminal helix have been noted to reduce enzyme
expression levels and activity (13). These observations led us to replace 5-LOX KKK653-655
with the corresponding sequence from 8R-LOX (ENL) in an effort to stabilize the enzyme
for crystallographic studies.
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The mutant human enzyme (herein referred to as Stable-5-LOX) was prepared in the context
of a soluble 5-LOX (Sol-5-LOX) which lacks putative membrane insertion amino acids
(Δ40-44GS, W13E, F14H, W75G, L76S) as well as a pair of Cysteines (C240A, C561A)
predicted to be proximal in the 5-LOX structure. Substitution of the membrane insertion
loops was based on a similar approach with the Plexaura homomalla enzyme, which shares
both these amino acids and Ca2+-binding residues with 5-LOX in the amino terminal
membrane-binding domain (14). The substitution of KKK with ENL in this context led to a
~3°C increase in the melting temperature of the enzyme (Fig 1C). Moreover, Stable-5-LOX
has a longer half-life at 37 °C (~16 hrs vs. ~7 hrs, Fig S2). Furthermore, Stable-5-LOX
produces both the intermediate 5S-HPETE and the product leukotriene A4 (Fig 1D), as does
its progenitor protein Sol-5-LOX (Fig S3). In addition, we measure a Km for AA of ~11μM
(Fig S4), equivalent to that of the wild-type enzyme (15). These observations are consistent
with the proposal that the KKK sequence is destabilizing, and that its substitution does not
impact catalytic fidelity. The structure of Stable-5-LOX was determined to 2.4 Å resolution
(Fig. 2A, S5; Table S1).
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The canonical LOX framework contains two distinct domains: the amino terminal “C2-like”
domain (~120 amino acids), which in 5-LOX confers Ca2+-dependent membrane binding
(16-19), and the larger catalytic domain. The latter is primarily α-helical and harbors the
non-heme catalytic iron. The iron is coordinated by three conserved histidines (His- 367,
372, 550) as well as the main-chain carboxylate of the C-terminus (I673). Another
structurally distinct conserved feature in this domain, previously described in detail by
Minor et al (20) for soybean LOX L-1, is an arched helix that shields access to the catalytic
iron. At the vertex of the Stable-5-LOX arched helix is Leu-414 (Fig 2B), an invariant
amino acid that in other lipoxygenases has been proposed to control access of O2 to the
substrate (21, 22) or position the substrate pentadiene for attack (7). Additional amino acids
from the arched helix that help define the catalytic site are Leu-420 and Phe-421. The crystal
structure of Stable-5-LOX reveals a striking variation on the classic lipoxygenase fold in
helix α2 which defines one edge of the active site. In the structures of 8R- and 15-LOX helix
α2 is 6-7 turns, while in Stable-5-LOX it is a short 3-turn helix flanked by extended loops.
The shortened helix is positioned at ~45° to its counterparts in the 8R- and 15S- enzymes
(Fig 3A,B). The unique orientation of helix α2 in Stable-5-LOX greatly limits access to the
catalytic iron and yields a distinctive active site cavity. Specifically, the side chains of F177
and Y181 are positioned inward and close off an access channel to the catalytic iron that is
observed in both the 8R- and 15-LOX structures (Fig. 2B, 4A). The remainder of the
secondary structural elements, and their relative orientations, are maintained (Fig 3B). In
addition, the structural context of the Lys-rich peptide also appears conserved as the Cterminal helices superimpose (Fig. 1A). However, it is apparent that a Lys at position 655
would interfere with invariant salt link and cation-π interactions (Fig 1B).
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In Stable-5-LOX the active site is an elongated cavity, with no clear access to bulk solvent,
lined with both invariant and 5-LOX specific amino acids. Leu- 368, 373, 414, 607 and
Ile-406 are conserved in all AA-metabolizing lipoxygenases (7) and form a structurally
similar constellation of branched hydrophobic side chains that envelop the region where the
pentadiene must be positioned for catalysis (Fig. 4A,B). Y181, A603, A606, H600 and T364
are specific to 5-LOX sequences and the small side chains of A603 and A606 appear to be
required for the conformation of Y181 which, along with F177, “corks” the cavity at one
end. Y181 is in van der Waals contact with A603, and the small side chains of both 603 and
606 allow both bulky aromatics (F177, Y181) to point into the cavity where they can be
shielded from solvent (Fig. 4C). An additional 5-LOX specific amino acid, W599, appears
to buttress the FY cork from one side. Amino acids Asn-407 and His-432 also help define
the active site.
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The closed cavity (volume = 663Å3) raises the question of how substrate gains access to the
catalytic iron. Two possibilities can be envisioned: (1) Removal of the FY cork at one end of
the cavity and/or movement of W599 that secures it, or (2) A rotamer shift of W147 at the
opposite end. A rotamer shift in W147 would require only rotation of the side chain, while
the former may require both side chain and main chain movements in two amino acids. This
observation suggests that AA may enter 5-LOX from the opposite direction as it does in the
15S- or 8R- enzymes, which lack the FY cork. This site of entry fits well with what is known
about the catalytic mechanism: H abstraction and peroxidation occur on opposite sides of the
pentadiene (23). The S-stereochemistry of the 5-LOX product is consistent with an “inverse”
orientation of AA relative to that for the 15S- and 8R- enzymes (24, 25). An opening at the
W147 end would allow the AA to enter methyl end first and position the substrate for the
production of the S isomer of 5-HPETE. While the above model is attractive, the structure
does not rule out the alternative: that the AA enters the same portal it does in 8R- and 15Senzymes. Carboxylate-first entry in this latter mode achieves the same binding orientation
and reaction specificity.
The 2.4 Å structure of Stable-5-LOX reveals an active site which, despite a conserved
constellation of five invariant amino acids, is clearly distinct from the active sites of the
arachidonic acid metabolizing lipoxygenases for which structures are available. The
structure provides a context for the development of 5-LOX specific inhibitors and together
with the crystal structures of FLAP (26) and the downstream enzyme Leukotriene C4
Synthase (27, 28), a molecular model for early events in leukotriene biosynthesis.
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Identification of a destabilizing sequence, possibly involved in function, allowed
crystallization of a key enzyme of the inflammatory response.
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Fig 1. Stabilization of human 5-LOX
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(A) Superposition of the C-terminal regions of the structures of 15-, 8R-, and Stable-5lipoxygenase. The C-terminal segment that leads to the catalytic Fe emanates from the helix
which terminates at amino acid 655 (5-LOX numbering; Stable-5-LOX, pink; 8R-LOX
green; 15-LOX, blue). Highly conserved amino acids (Leu, Phe/Tyr) and an invariant salt
link (Asp-Arg) are depicted in stick rendering. (B) Detail of the turn at the end of the
terminal helix. The 5-LOX specific Lys (substituted in Stable-5-LOX with Leu) is modeled
at position 655 as its most common rotamer (transparent sphere rendering). As positioned, it
would interfere with the invariant salt-link and cation- π interactions. All figures were
generated with Pymol (29). (C) Thermal denaturation of Stable-5-LOX (red) and the parent
enzyme Sol-5-LOX (blue). Fluorescence (F) is monitored as a function of temperature. Tm
(with s.d.) 56.6 (±0.4) and 59.7(±0.2) °C for Sol-5-LOX and Stable-5-LOX, respectively.
(D) HPLC chromatogram. Product analysis of Stable-5-LOX reveals both 5-HETE (5HPETE reduced by the addition of triphenylphosphine, TPP) and Leukotriene A4 hydrolysis
products (5,12 diols).
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Fig 2. The structure of Stable-5-LOX
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(A) A cartoon rendering of 5-LOX. The two views differ by a 180° rotation about the
vertical line. The amino terminal C2-like domain is in dark gray, and the catalytic domain in
light gray. The distinctive arched helix is in blue, and helix α2 in red. The internal cavity,
generated with CastP (30), is in pink and the Fe is an orange sphere. The positions of the
mutated amino acids are indicated in mesh rendering: green, putative membrane insertion
residues; yellow, proximal cysteines; and blue, the KKK→ENL substitution. (B). Detail of
the relationship of the arched helix and helix α2 to the active site as viewed from the
perspective indicated by the red arrow in panel (A). Shown in stick rendering are amino
acids 406, 414, 420, 421 of the arched helix and F177 and Y181 from helix α2 (with
transparent surface rendering). The latter two bulky amino acids obstruct access to the
cavity. The proximity of the C-terminal Ile (673) to the corked portal is apparent.
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Fig. 3. (A) The positioning of helix α2 is unique in 5-LOX

(A) A 5-LOX cartoon is rendered in pink, 15-LOX in blue and 8R-LOX in green. Conserved
aromatic amino acids (F169,W201) that flank the region are in stick rendering. F177 and
Y181 that make up the “cork” that helps define the active site are in stick. The catalytic iron
is an orange sphere. (B) A full overlay of the three structures in which it is apparent that,
with the exception of α2, the secondary structural elements in the enzymes are conserved.
The box indicates the region amplified in (A).
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Fig 4. The 5-LOX active site
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Internal cavities calculated with CastP (30). (A) The active site cavity of 15-LOX (2P0M) is
in yellow. Invariant Leu and Ile side chains are in green stick rendering. The 5-LOX “FY
cork” is superposed on the 15-LOX cavity and plugs the entrance. (B) The equivalent
orientation of the active site cavity of Stable-5-LOX in pink; invariant Leu and Ile side
chains in green sticks. Note the similarity of the positions of these amino acids to their
counterparts in 15-LOX (A). Iron coordination sphere amino acids (C, white) are in stick
rendering, and the iron an orange sphere. (C) 5-LOX amino acids that contribute to the
active site cavity. Entry into this cavity requires a conformational change.

NIH-PA Author Manuscript
Science. Author manuscript; available in PMC 2011 December 23.

